DIAGNOSTIC AND THERAPEUTIC NUCLEAR MEDICINE FOR NEUROENDOCRINE TUMORS

1. Classification of Neuroendocrine Neoplasms
2. Molecular Genetics of Pheochromocytoma and Paraganglioma
3. Molecular Genetics of MEN1-Related Neuroendocrine Tumors
4. Molecular Genetics of MEN2-Related Neuroendocrine Tumours
5. Molecular Genetics of Neuroblastoma
6. Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumours
7. Current and Future Radiopharmaceuticals in Neuroendocrine Tumor Imaging
8. SPECT/CT, PET/CT and PET/MR Principles
9. Internal Dosimetry: Principles and Applications to NET
10. Principles and Application of Molecular Imaging for Personalized Medicine and Guiding Interventions in Neuroendocrine Tumors
11. Tumor Metabolism and Metabolomics of Pheochromocytomas and Paragangliomas
12. Radionuclide Imaging of Pheochromocytoma and Paraganglioma in the Era of Multi-omics
13. Radionuclide Imaging of Head and Neck Paragangliomas
14. Radionuclide Imaging of Chromaffin Cell Tumors
15. Radionuclide Imaging of Gastrointestinal Neuroendocrine Tumors
16. Radionuclide Imaging of Pancreatic Neuroendocrine Tumours
17. Radionuclide Imaging of Pulmonary and Thymic Neuroendocrine Tumors
18. Radionuclide Imaging of Medullary Thyroid Carcinoma
19. 131I-Meta-Iodobenzylguanidine Therapy for Pheochromocytoma/Paraganglioma and Neuroblastoma
20. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
21. Alpha Radionuclide Therapy: Principles and Applications to NETs
22. Nanoparticles for Radionuclide Imaging and Therapy: Principles

Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles.
Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.

Features
• A unique presentation of novel functional radionuclide imaging and therapies for the location and treatment of neuroendocrine tumors
• Discusses embryology and classification, molecular genetics, physics and technology in addition to the most up-to-date radiology and management strategies
• Represents a collaborative effort endocrinologists, radiologists, oncologists, geneticists and surgeons

Authors
• Karel Pacak, MD, PhD, DSc, Senior Investigator and Chief, Section on Medical Neuroendocrinology, Professor of Medicine, Eunice Kennedy Shriver NICHD/NIH, Bethesda, MD, USA
• David Taieb, MD, PhD, Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France